Semicarbazide-sensitive amine oxidase (SSAO): Present and future

Inflammopharmacology

Volumn 11, Issue 2, 2003, Pages 165-173

  Magyar, Kálmán ^a   Mészáros, Zsuzsa ^a  

^a SEMMELWEIS UNIVERSITY   (Hungary)

Author keywords

Atherosclerosis; Diabetes mellitus; Parkinson's disease; Retinopathy; Varicose veins

Indexed keywords

2 (3,4 DIMETHOXYPHENYL) 3 FLUOROALLYLAMINE; 4 AMINOMETHYL 3,5 DIETHOXYPYRIDINE; AMIFLAMINE; AMINE OXIDASE (COPPER CONTAINING); AMINOGUANIDINE; BENSERAZIDE; CARBIDOPA; HYDRALAZINE; HYDROXYLAMINE; IPRONIAZID; MEXILETINE; MOFEGILINE; MONOAMINE OXIDASE INHIBITOR; PHENELZINE; PROCARBAZINE; PROPARGYLAMINE; PYRIDOXAMINE; SEMICARBAZIDE; UNCLASSIFIED DRUG;

ADULT; ARTERY DIAMETER; ARTERY INTIMA; ARTICLE; ATHEROSCLEROSIS; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; DEAMINATION; ENZYME ACTIVITY; ENZYME BLOOD LEVEL; ENZYME INHIBITION; ENZYME STRUCTURE; FEMALE; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; RELIABILITY;

EID: 0038389838     PISSN: 09254692     EISSN: None     Source Type: Journal    
DOI: 10.1163/156856003765764335     Document Type: Article

References (21)

1. Boomsma, F., van den Meiracker, A., Man in 't Veld, A., et al. (1995). Contrasting effects of peripheral decarboxylase inhibitors on plasma activity of aromatic-L-amino acid decarboxylase and emicarbazide-sensitive amine oxidase in Parkinson's disease, Life Sci. 57, 1753-1759.
2. Boomsma, F., van Veldhuisen, D. J., de Kam, P. J., et al. (1997). Plasma semicarbazide-sensitive amine oxidase is elevated in patients with congestive heart failure, Cardiovasc. Res. 33, 387-391.
3. Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein dye-binding, Anal. Biochem. 72, 248-254.
4. Callingham, B. A., Holt, A. and Elliott, J. (1990). Some aspects of the pharmacology of semicarbazide-sensitive amine oxidases, J. Neural Transm. (Suppl.) 32, 279-290.
5. Deng, Y. and Yu, P. H. (1999). Simultaneous determination of formaldehyde and methylglyoxal in urine: involvement of semicarbazide-sensitive amine oxidase-mediated deamination in diabetic complications, J. Chromatogr. Sci. 37, 317-322.
6. Elliott, J., Callingham, B. A. and Barrand, M. A. (1989). In-vivo effects of (E)-2-(3′,4′-dimethoxyphenyl)-3-fluoroallylamine (MDL 72145) on amine oxidase activities in the rat. Selective inhibition of semicarbazide-sensitive amine oxidase in vascular and brown adipose tissues, J. Pharm. Pharmacol. 41, 37-41.
7. Fitzgerald, D. H., Tipton, K. F. and Lyles, G. A. (1998). Studies on the behaviour of semicarbazide-sensitive amine oxidase in Sprague-Dawley rats treated with the monoamine oxidase inhibitor tranylcypromine. J. Neural Transm. (Suppl.) 52, 259-264.
8. Garpenstrand, H., Ekblom, J., von Arbin, M., et al. (1999). Plasma semicarbazide-sensitive amine oxidase in stroke, Eur. Neurol. 41, 20-23.
9. Garpenstrand, H., Ekblom, J., Backlund, L. B., et al. (1999). Elevated plasma semicarbazide-sensitive amine oxidase (SSAO) activity in Type 2 diabetes mellitus complicated by retinopathy, Diabet. Med. 16, 514-521.
10. Guffroy, C. and Strolin Benedetti, M. (1984). Monoamine oxidase and semicarbazide-sensitive amine oxidase in spontaneously hypertensive and in normotensive control rats, Life Sci. 34, 535-545.
11. Lizcano, J. M., Balsa, D., Tipton, K. F., et al. (1991). The oxidation of dopamine by the semicarbazide-sensitive amine oxidase (SSAO) from rat vas deferens, Biochem. Pharmacol. 41, 1107-1110.
12. Lyles, G. A. (1994). Properties of mammalian tissue-bound semicarbazide-sensitive amine oxidase: possible clues to its physiological function? J. Neural Transm. (Suppl.) 41, 387-396.
13. Lyles, G. A. (1996). Mammalian plasma and tissue-bound semicarbazide-sensitive amine oxidases: biochemical, pharmacological and toxicological aspects, Int. J. Biochem. Cell Biol. 28, 259-274.
14. Meszaros, Z., Szombathy, T., Raimondi, L., et al. (1999). Elevated serum semicarbazide-sensitive amine oxidase activity in non-insulin-dependent diabetes mellitus: correlation with body mass index and serum triglyceride, Metabolism 48, 113-117.
15. Palfreyman, M. G., McDonald, I. A., Bey, P., et al. (1994). Haloallylamine inhibitors of MAO and SSAO and their therapeutic potential, J. Neural Transm. (Suppl.) 41, 407-414.
16. Yu, P. H., Davis, B. A., Boulton, A. A., et al. (1994). Deamination of aliphatic amines by type B monoamine oxidase and semicarbazide-sensitive amine oxidase, pharmacological implications, J. Neural Transm. (Suppl.) 41, 397-406.
17. Yu, P. H. and Deng, Y. L. (1998). Endogenous formaldehyde as a potential factor of vulnerability of atherosclerosis: involvement of semicarbazide-sensitive amine oxidase-mediated methylamine turnover, Atherosclerosis 140, 357-363.
18. Yu, P. H., Lai, C. T. and Zuo, D. M. (1997). Formation of formaldehyde from adrenaline in vivo; a potential risk factor for stress-related angiopathy, Neurochem. Res. 22, 615-620.
19. Yu, P. H. and Zuo, D. M. (1997). Aminoguanidine inhibits semicarbazide-sensitive amine oxidase activity: implications for advanced glycation and diabetic complications, Diabetologia 40, 1243-1250.
20. Yu, P. H. and Zuo, D. M. (1993). Oxidative deamination of methylamine by semicarbazide-sensitive amine oxidase leads to cytotoxic damage in endothelial cells. Possible consequences for diabetes, Diabetes 42, 594-603.
21. Zuo, D. M. and Yu, P. H. (1994). Semicarbazide-sensitive amine oxidase and monoamine oxidase in rat brain microvessels, meninges, retina and eye sclera, Brain Res. Bull. 33, 307-311.